‘Montu has been discounting products and offering incentives to pharmacies to order through its platform. While neither strategy is regarded as improper business conduct, it is not unusual for brands – regardless of industry – to become frustrated at behaviour which they believe results in their product being undervalued, or cheapened’
A showdown is brewing between two of the industry’s heavyweight companies over claims a top-selling medicinal cannabis product is unreliable and not up to scratch.
In a potentially incendiary communication seen by Cannabiz, Montu has told patients it has discontinued Cannatrek’s T25 Topaz flower “due to poor reliability or quality”.